Cautious on The Medicines Company - Analyst Blog

1Z1-20669_6_9

Publication: Zacks Investment Research - Analyst Blog

Date: 2009-06-02 00:00:00

Cautious on The Medicines Company - Analyst Blog

In mid-May 2009, The Medicines Company ( MDCO ) announced that an interim analysis review committee (IARC), along with the data safety monitoring board (DSMB), after conducting a review of the ongoing CHAMPION phase III program with Cangrelor, notified the company that the ongoing CHAMPION-PLATFORM program would not meet the primary endpoint of a persuasive evidence of clinical effectiveness that could serve as the basis for regulatory approval.

The IARC DSMB noted that the phase III ...

To read the rest of the article, click here to take a free trial!